As of 2026-04-12, the Relative Valuation of Urogen Pharma Ltd (URGN) is (33.03) USD. This relative valuation is based on P/E multiples. With the latest stock price at 21.57 USD, the upside of Urogen Pharma Ltd based on Relative Valuation is -253.1%.
The range of the Relative Valuation is (15.70) - (47.04) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 5.0x - 17.8x | 11.4x |
| Forward P/E multiples | 4.2x - 14.9x | 9.6x |
| Fair Price | (15.70) - (47.04) | (33.03) |
| Upside | -172.8% - -318.1% | -253.1% |
| Date | P/E |
| 2026-04-10 | -6.84 |
| 2026-04-09 | -6.51 |
| 2026-04-08 | -6.06 |
| 2026-04-07 | -5.72 |
| 2026-04-06 | -5.90 |
| 2026-04-02 | -5.97 |
| 2026-04-01 | -6.01 |
| 2026-03-31 | -5.70 |
| 2026-03-30 | -5.39 |
| 2026-03-27 | -5.45 |
| 2026-03-26 | -5.68 |
| 2026-03-25 | -5.75 |
| 2026-03-24 | -5.60 |
| 2026-03-23 | -5.49 |
| 2026-03-20 | -5.59 |
| 2026-03-19 | -5.90 |
| 2026-03-18 | -5.86 |
| 2026-03-17 | -5.90 |
| 2026-03-16 | -5.94 |
| 2026-03-13 | -5.85 |
| 2026-03-12 | -5.96 |
| 2026-03-11 | -5.98 |
| 2026-03-10 | -6.17 |
| 2026-03-09 | -6.31 |
| 2026-03-06 | -6.49 |
| 2026-03-05 | -6.22 |
| 2026-03-04 | -6.39 |
| 2026-03-03 | -5.97 |
| 2026-03-02 | -6.03 |
| 2026-02-27 | -6.88 |
| 2026-02-26 | -6.72 |
| 2026-02-25 | -6.56 |
| 2026-02-24 | -6.58 |
| 2026-02-23 | -6.63 |
| 2026-02-20 | -6.68 |
| 2026-02-19 | -6.91 |
| 2026-02-18 | -7.06 |
| 2026-02-17 | -6.53 |
| 2026-02-13 | -6.37 |
| 2026-02-12 | -6.41 |
| 2026-02-11 | -6.70 |
| 2026-02-10 | -6.87 |
| 2026-02-09 | -6.95 |
| 2026-02-06 | -6.77 |
| 2026-02-05 | -6.51 |
| 2026-02-04 | -6.57 |
| 2026-02-03 | -6.34 |
| 2026-02-02 | -6.25 |
| 2026-01-30 | -6.22 |
| 2026-01-29 | -6.56 |